Apricus Biosciences (APRI) Tops Q3 EPS by 1c

Apricus Biosciences (NASDAQ: APRI) reported Q3 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Apricus Biosciences (APRI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c